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Accumulating studies, both inanimalsandhumanclinical trialswithmesenchymal stromacells (MSC) support
the hypothesis of therapeutic effects of these cells in various disorders. However, despite success in immune-
mediated disorders such as Crohns' disease, lung disorders such as chronic obstructive pulmonary disease
(COPD) and idiopathic pulmonarydisease (IPF) treatedwithMSC have so far not yielded a revolutionary effect
on clinical symptoms. Promising data on immunomodulatory effects in COPD have kept nourishing the
research into ﬁnding speciﬁc traits of MSC beneﬁcial in disease. A heterogeneous population of injected cells
might drown a potential therapeutic role of a speciﬁc group of MSC. Thus careful analysis of MSC regarding
their molecular capabilities such as delivering speciﬁc therapeutic vesicles to the environment, or plain
cytokine/chemokine ﬁngerprinting might prove useful in augmenting therapies against lung diseases.
© 2014 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).1. Background
Over the last decades, promising results have been generated for
cell-based therapies with somatic stem cells in models of serious
lung disorders such as acute respiratory distress syndrome [1].
Accumulating data from several clinical trials indicates that trans-
plantation of bone marrow or adipose derived mesenchymal
stroma cells (MSC) to patients is safe and non-toxic [2]. Moreover,
MSC have been demonstrated to exert a beneﬁcial effect in both
phase 1 and 2 clinical trials in immune-mediated diseases such as
graft-versus-host disease (GVHD) [3] and Crohn's disease [4].
However, data are not consistent and other studies have even
showed opposing effects of MSC in GVHD [5].
2. MSC-based therapies e importance of clinical trial set-up
Despite promising results from the clinical applications in
immunological diseases, less success has been achieved in other
disorders. Clinical trials with autologous MSC in heart diseases like(ofﬁce), þ46 72 249 4600
arlsson).
s article under the CC BY-NC-ND lmyocardial infarction and heart failure have so far not succeeded
[6,7]. In line, a clinical randomized placebo-controlled trial ofMSC in
chronicobstructivepulmonarydisease (COPD) showednosigniﬁcant
amelioration in pulmonary function or frequency of exacerbations.
However an early decrease in C-reactive protein (CRP) still gives
promise for future investigations [8]. Weiss et al. used allogeneic
bone marrow derived MSC from healthy donors and patients were
either treatedwith intravenous infusion ofMSC or vehicle (placebo).
Importantly, their study demonstrates that intravenous infusion of
bonemarrowderivedMSC is safe inpatients suffering fromCOPD[8].
Additionally, a prospective, non-randomized, non-placebo-
controlled phase Ib trial was performed on patients with idiopathic
pulmonary ﬁbrosis (IPF). Here, autologous MSC derived from lipo-
aspirations were used. The MSC were diluted in saline and given
by endobronchial infusions. This administration route is different
from the intravenous application applied in most studies so far;
nevertheless the results showed that endobronchial administration
of adipose-derived stem cells is safe in IPF patients [9].3. MSC treatment in lung disorders
Chronic lung diseases, like COPD and asthma, represent aworld-
wide high socio-economic burden and COPD is today the fourthicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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place by 2020 [10]. Therapies manage to control, in most cases, the
inﬂammation, but no cure exists and the remodeling of lung tissue
leads to chronicity and the deleterious decline in lung function. The
only treatment that is available for patients with end-stage lung
diseases is lung-transplantation but unfortunately, 50e60% of the
lung-transplanted patients develop chronic rejection [11,12]. In
light of the success of cell therapy in blood disorders, lots of
attention and efforts are being put into developing successful cell
therapies and particularly MSC therapies also for chronic lung
disorders. There is hope that MSCmight be able to affect the course
of the disease e potentially preventing development of bronchio-
litis obliterans syndrome (BOS).
Besides adipose and bone marrow derived MSC, there is an
increasing interest also in lung-resident MSC. Evolving evidence
points toward lung resident MSC that have been isolated from
bronchoalveolar lavage ﬂuid from lung-transplanted patients [13]
and also from lung tissue [14]. We have recently demonstrated
that MSC can be isolated from lung tissue of lung-transplanted
patients both from central and peripheral locations within the
lung. Furthermore, we have isolated primary MSC based on the
expression of CD90/CD105 and we showed that they are located
perivascularly [15]. We and others have further described that MSC
are tissue speciﬁc and differ from bone marrow derived MSC
phenotypically as well as functionally [15,16].
4. Therapeutic effects of MSC
It has been reported that the majority of MSC are trapped within
the lung after intravenous administration in different animal
models, however, pulmonary engraftment has been demonstrated
to be very low, after both, transtracheal e [17] and systemic
administration [18]. Therefore, the effect of MSC treatment has
been suggested to result from paracrine mechanisms rather than
through engraftment or differentiation. Following systemic
administration, MSC initially localize in lung and the existence of
lung injury may attract the MSC and prolong their retention in the
lung. Locally, the MSC have been described to secrete a variety of
cytokines and growth factors including TNF-stimulated gene-6
(TSG-6), which is an anti-inﬂammatory protein that interestingly
also is involved in hyaluronan deposition [19,20]. There are studies
suggesting that conditioned medium from MSC is sufﬁcient for
improving acute lung injury and that the MSC themselves are
redundant [21]. Interestingly, MSC have been shown to secrete
microvesicles that might have a larger impact than what has pre-
viously been appreciated [22]. Microvesicles can transfer for
example mRNA, miRNA, signal molecules, and surface receptors. A
proteomic analysis on microvesicles isolated from bone marrow
derived MSC revealed that they contain at least 730 proteins,
whereof a few of them were suggested to be associated with the
therapeutic effect [23]. These promising data thus open new ave-
nues for treatment of various lung diseases.
5. Conclusions
Despite promising results both in animal models of lung disor-
ders and clinical studies, there is e as unfortunately also observed
in other (stem) cell therapy areas e an unjustiﬁed hope and hype
that cell-based treatments will help to cure all lung diseases within
a short time. Before succeeding with MSC treatment of lung dis-
eases, however, open questions regarding the basic biology of MSC
and especially lung-derived MSC need to be thoroughly investi-
gated. Important questions regarding lung MSC relate to their
physiological role in the normal lung and their possible involve-
ment in pathological processes. Recent research indicates that amore precise sub-division of speciﬁc diseases and importantly, the
speciﬁc sub-grouping of MSC will be a future challenge. In fact, a
growing body of evidence indicates that the therapeutic effect of
MSC in various conditions is mediated by different MSC subtypes,
which are part of a heterogeneous pool of different MSC. TheseMSC
subtypes might show a different homing capacity to the lung,
thereby exerting their cell-speciﬁc effect [24].
Thorough care needs to be taken to characterize speciﬁc path-
ological conditions. Future research on MSC therapy in lung dis-
orders may shed light on speciﬁc functions of different
homogeneous subsets of MSC and hopefully allow designing a
tailor-made treatment according to patient-speciﬁc conditions.
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